| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Twan Lammers | Q58775917 |
| Roy van der Meel | Q63866819 | ||
| Wim Hennink | Q88507232 | ||
| P2860 | cites work | Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin | Q89286947 |
| Challenges and strategies in anti-cancer nanomedicine development: An industry perspective | Q26748018 | ||
| A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs | Q28285226 | ||
| Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. | Q32107154 | ||
| Mechanism of hard-nanomaterial clearance by the liver. | Q37462904 | ||
| Remote loading of preencapsulated drugs into stealth liposomes | Q37587698 | ||
| Analysis on the current status of targeted drug delivery to tumors | Q38026625 | ||
| Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status | Q38135674 | ||
| Extracellular vesicles as drug delivery systems: lessons from the liposome field | Q38237168 | ||
| Antibody-drug conjugates for cancer therapy. | Q38864720 | ||
| Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo. | Q38911659 | ||
| Cancer nanomedicine: Is targeting our target? | Q41169917 | ||
| Lessons in simplicity that should shape the future of drug delivery | Q48361564 | ||
| Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. | Q50629316 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanomedicine | Q261659 |
| P304 | page(s) | 1-5 | |
| P577 | publication date | 2016-11-17 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Cancer nanomedicines: oversold or underappreciated? | |
| P478 | volume | 14 |
| Q38557650 | Applying nanomedicine in maladaptive inflammation and angiogenesis |
| Q94547315 | Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies |
| Q64947947 | Encapsulation of Gold Nanorods with Porphyrins for the Potential Treatment of Cancer and Bacterial Diseases: A Critical Review. |
| Q91829463 | Evaluation of particle size techniques to support the development of manufacturing scale nanoparticles for application in pharmaceuticals |
| Q92644551 | Improving nanotherapy delivery and action through image-guided systems pharmacology |
| Q94562267 | Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease |
| Q52662884 | Nanoscale artificial antigen presenting cells for cancer immunotherapy. |
| Q92069823 | Recalcitrant Issues and New Frontiers in Nano-Pharmacology |
| Q91152077 | Smart cancer nanomedicine |
| Q47690085 | Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems |
| Q47142621 | Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies. |
| Q49787181 | Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer. |
| Q47622098 | Targeted inhibition of human hematological cancers in vivo by doxorubicin encapsulated in smart lipoic acid-crosslinked hyaluronic acid nanoparticles |
Search more.